MARKET

AXSM

AXSM

Axsome
NASDAQ

Real-time Quotes | Nasdaq Last Sale

34.02
+1.31
+4.00%
Opening 15:10 11/21 EST
OPEN
32.85
PREV CLOSE
32.71
HIGH
34.95
LOW
31.61
VOLUME
1.35M
TURNOVER
--
52 WEEK HIGH
34.95
52 WEEK LOW
1.940
MARKET CAP
1.17B
P/E (TTM)
-21.1897
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AXSM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AXSM News

  • The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon
  • Benzinga.7h ago
  • Axsome Therapeutics to Host Investor R&D Call with Key Opinion Leaders Focusing on AXS-07 and the Unmet Needs in the Acute Treatment of Migraine
  • GlobeNewswire.8h ago
  • Edited Transcript of AXSM earnings conference call or presentation 7-Nov-19 1:00pm GMT
  • Thomson Reuters StreetEvents.1d ago
  • The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data
  • Benzinga.1d ago

More

Industry

Biotechnology & Medical Research
-0.41%
Pharmaceuticals & Medical Research
+0.28%

Hot Stocks

Name
Price
%Change

About AXSM

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).
More

Webull offers Axsome Therapeutics Inc (AXSM) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.